Back to Search
Start Over
A phase II study of triazinate (NSC 139105) in advanced colorectal carcinoma.
- Source :
-
Cancer [Cancer] 1977 Jul; Vol. 40 (1), pp. 9-13. - Publication Year :
- 1977
-
Abstract
- Triazinate (Baker's Antifol, NSC 139105) was given to 28 patients as a single agent in the chemotherapy of advanced colerectal carcinoma. The dosage utilized was 250 mg/m2 intravenously, administered daily in three consecutive days. Patients were evaluated at three weeks, six weeks, and then monthly until progression was evident. Various immunologic determinants (i.e., DNCB sensitization, immunoglobulins, recall skin tests, lymphocyte blastogenesis, and circulating lymphocytes, T-cells and B-cells) were obtained prior to treatment and at each re-evaluation. The principal side effects were dermatitis, stomatitis, diarrhea, nausea, somnolence, and leukopenia. There was no discernable effect of Triazinate on the immunologic determinants tested. There was one complete response, and four partial responses, for an objective regression rate of 18%. This study suggests that Triazinate has a definite, though limited, effect on advanced colorectal carcinoma.
- Subjects :
- Adenocarcinoma immunology
Adult
Aged
Colonic Neoplasms immunology
Diarrhea chemically induced
Drug Eruptions etiology
Female
Folic Acid Antagonists adverse effects
Humans
Immunoglobulins analysis
Leukopenia chemically induced
Lymphocyte Activation
Male
Middle Aged
Nausea chemically induced
Rectal Neoplasms immunology
Skin Tests
Stomatitis chemically induced
Thrombocytopenia chemically induced
Triazines adverse effects
Adenocarcinoma drug therapy
Colonic Neoplasms drug therapy
Folic Acid Antagonists therapeutic use
Rectal Neoplasms drug therapy
Triazines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 0008-543X
- Volume :
- 40
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 141977
- Full Text :
- https://doi.org/10.1002/1097-0142(197707)40:1<9::aid-cncr2820400104>3.0.co;2-6